These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections. Wang JT, Liao HI, Wu Lin FL, Chang SC. Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355 [Abstract] [Full Text] [Related]
6. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics. Niwa T, Imanishi Y, Ohmori T, Matsuura K, Murakami N, Itoh Y. Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275 [Abstract] [Full Text] [Related]
8. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days. Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Takai Y, Yamada K, Tsuchida T, Otani N, Takahashi Y, Ishihara M, Takubo S, Ikeuchi H, Uchino M, Kimura T. BMC Pharmacol Toxicol; 2020 Jul 08; 21(1):50. PubMed ID: 32641110 [Abstract] [Full Text] [Related]
12. Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections. Bantar C, Durlach R, Nicola F, Freuler C, Bonvehí P, Vazquez R, Smayevsky J. J Antimicrob Chemother; 1999 May 08; 43(5):737-40. PubMed ID: 10382901 [Abstract] [Full Text] [Related]
14. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction. Ueda T, Takesue Y, Nakajima K, Ichiki K, Doita A, Wada Y, Tsuchida T, Takahashi Y, Ishihara M, Ikeuchi H, Uchino M, Kimura T. Eur J Clin Microbiol Infect Dis; 2016 Sep 08; 35(9):1501-9. PubMed ID: 27278654 [Abstract] [Full Text] [Related]
15. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults. Rouveix B, Jehl F, Drugeon H, Brumpt I, Caulin E. Antimicrob Agents Chemother; 2004 Jul 08; 48(7):2394-9. PubMed ID: 15215086 [Abstract] [Full Text] [Related]
17. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. J Infect Chemother; 2012 Feb 08; 18(1):10-6. PubMed ID: 21710160 [Abstract] [Full Text] [Related]
18. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection. Zhang XS, Chen YL, Wang YZ, Chen C, Chen YJ, Xu FM, Dai Y, Shi DW, Lin GY, Yu XB, Xiang DZ, Zhang CH. Br J Clin Pharmacol; 2024 Feb 08; 90(2):452-462. PubMed ID: 37749762 [Abstract] [Full Text] [Related]